Meeting
2022 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Authors
Gordan Srkalovic
Sparrow Cancer Center, Michigan Cancer Research Consortium, Ypsilanti, MI
Gordan Srkalovic , Michael Rothe , Pam K. Mangat , Elizabeth Garrett-Mayer , Reza Nazemzadeh , Timothy Lewis Cannon , Herbert Leon Duvivier , Kathleen J Yost , Suchita Pakkala , Ajjai Shivaram Alva , Deepti Behl , Philip Jordan Gold , Carmen Julia Calfa , Melissa Ngirailemesang , Steven Francis Powell , Raegan O'Lone , Gina N. Grantham , Susan Halabi , Richard L. Schilsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT02693535
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3114)
DOI
10.1200/JCO.2022.40.16_suppl.3114
Abstract #
3114
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Jean L. Grem
Poster
2023 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Carmen Julia Calfa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Tareq Al Baghdadi